Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,729 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.
Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, Scarpellini E, Vincenti F, Cammarota G, Flore R, Pola P, Gasbarrini G, Gasbarrini A. Lauritano EC, et al. Among authors: gasbarrini a, gasbarrini g. Aliment Pharmacol Ther. 2005 Jul 1;22(1):31-5. doi: 10.1111/j.1365-2036.2005.02516.x. Aliment Pharmacol Ther. 2005. PMID: 15963077 Free article. Clinical Trial.
Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.
Lupascu A, Gabrielli M, Lauritano EC, Scarpellini E, Santoliquido A, Cammarota G, Flore R, Tondi P, Pola P, Gasbarrini G, Gasbarrini A. Lupascu A, et al. Among authors: gasbarrini a, gasbarrini g. Aliment Pharmacol Ther. 2005 Dec;22(11-12):1157-60. doi: 10.1111/j.1365-2036.2005.02690.x. Aliment Pharmacol Ther. 2005. PMID: 16305730 Free article.
High dosage rifaximin for the treatment of small intestinal bacterial overgrowth.
Scarpellini E, Gabrielli M, Lauritano CE, Lupascu A, Merra G, Cammarota G, Cazzato IA, Gasbarrini G, Gasbarrini A. Scarpellini E, et al. Among authors: gasbarrini a, gasbarrini g. Aliment Pharmacol Ther. 2007 Apr 1;25(7):781-6. doi: 10.1111/j.1365-2036.2007.03259.x. Aliment Pharmacol Ther. 2007. PMID: 17373916 Free article. Clinical Trial.
Probiotics: which and when?
Scarpellini E, Cazzato A, Lauritano C, Gabrielli M, Lupascu A, Gerardino L, Abenavoli L, Petruzzellis C, Gasbarrini G, Gasbarrini A. Scarpellini E, et al. Among authors: gasbarrini a, gasbarrini g. Dig Dis. 2008;26(2):175-82. doi: 10.1159/000116776. Epub 2008 Apr 21. Dig Dis. 2008. PMID: 18431068 Review.
Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole.
Lauritano EC, Gabrielli M, Scarpellini E, Ojetti V, Roccarina D, Villita A, Fiore E, Flore R, Santoliquido A, Tondi P, Gasbarrini G, Ghirlanda G, Gasbarrini A. Lauritano EC, et al. Among authors: gasbarrini a, gasbarrini g. Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):111-6. Eur Rev Med Pharmacol Sci. 2009. PMID: 19499846 Clinical Trial.
Isolation and characterization of CD133+ cell population within human primary and metastatic colon cancer.
Puglisi MA, Sgambato A, Saulnier N, Rafanelli F, Barba M, Boninsegna A, Piscaglia AC, Lauritano C, Novi ML, Barbaro F, Rinninella E, Campanale C, Giuliante F, Nuzzo G, Alfieri S, Doglietto GB, Cittadini A, Gasbarrini A. Puglisi MA, et al. Among authors: gasbarrini a. Eur Rev Med Pharmacol Sci. 2009 Mar;13 Suppl 1:55-62. Eur Rev Med Pharmacol Sci. 2009. PMID: 19530513
Small bowel bacterial overgrowth and type 1 diabetes.
Ojetti V, Pitocco D, Scarpellini E, Zaccardi F, Scaldaferri F, Gigante G, Gasbarrini G, Ghirlanda G, Gasbarrini A. Ojetti V, et al. Among authors: gasbarrini a, gasbarrini g. Eur Rev Med Pharmacol Sci. 2009 Nov-Dec;13(6):419-23. Eur Rev Med Pharmacol Sci. 2009. PMID: 20085122
1,729 results